Clinical Trial Update: A Uremic Toxin Absorbent (AST-120) to Treat Hospital Acquired Acute Kidney Injury [Phase 3]

View source ↗

Summary

Clinical trial update on AST-120 (an uremic toxin absorbent) for hospital-acquired acute kidney injury in Phase 3.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Kidney Injury

Drugs mentioned

• AST-120 (AST-120)

Snippet

Sponsor: National Taiwan University Hospital | Conditions: Acute Kidney Injury | Phase 3 | Status: UNKNOWN